Galmed Pharmaceuticals
GLMD
9 hedge funds and large institutions have $143K invested in Galmed Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
273% more capital invested
Capital invested by funds: $38.3K → $143K (+$104K)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
29% more funds holding
Funds holding: 7 → 9 (+2)
0.32% more ownership
Funds ownership: 0.05% → 0.37% (+0.32%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$86K |
| 2 |
Morgan Stanley
New York
|
+$42.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$406 |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$7 |
GLMD Hedge Fund Activity: Q4 2024 in Review
9 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2024, worth a combined $143K — up 273% from $38.3K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new GLMD positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $86K. The largest seller was Tower Research Capital (TRC), cutting an estimated $406.
- 9 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2024, up from 7 in Q3 2024.
- Funds reported $143K of Galmed Pharmaceuticals stock for Q4 2024, up 273% quarter-over-quarter.
- 2 funds opened new Galmed Pharmaceuticals positions in Q4 2024 and 0 closed out, a net change of +2 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2024 was Schonfeld Strategic Advisors, an estimated $86K added.
- The largest Galmed Pharmaceuticals seller in Q4 2024 was Tower Research Capital (TRC), an estimated $406 sold.
Based on aggregated 13F filings for Q4 2024.